- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00083629
Use of [18F]FECNT in Positron Emission Tomography
PET Whole Body Biodistribution and Test Retest Brain Imaging Studies Using a Dopamine Transporter Ligand [18F]FECNT
This study will examine the use of a new radioactive tracer called [18F]FECNT in positron emission tomography (PET) scanning for measuring dopamine transporter (DAT) in the brain. DAT is found in brain neurons (nerve cells) that release the chemical messenger dopamine. By taking pictures of the DAT, scientists hope to learn more about the function of these neurons.
Normal, healthy volunteers between 18 and 65 years of age may be eligible for this study. Candidates are screened with a medical history and physical examination, psychological assessment, and blood and urine tests.
Subjects enrolled in the study participate in one of the following procedures:
Brain Imaging Study: Part 1
Two catheters (small plastic tubes) are placed into veins in the subject's arms for injecting [18F]FECNT and for collecting blood samples during the scan. A third catheter is placed into a wrist artery to obtain arterial blood during the scan. With the catheters in place, the subject lies down on the scanner bed with his or her head placed in a special mask that limits movement during the brain scan. The scan begins with an initial x-ray like picture for about 10 minutes, after which the [18F]FECNT is injected and the actual PET scan starts. The entire procedure takes about 6 hours, including 2 hours of continuous scanning sessions, during which the subject is required to lie still. Subjects can relax out of the scanner between scans. They are monitored throughout the procedure. Vital signs are measured and electrocardiogram is taken once before and twice after injection of the tracer. At the end of the scanning, additional blood and urine samples are collected. Subjects are asked to urinate every 2 hours to lessen the radioactivity in the body.
Whole Body Imaging Study: Part 2
For this procedure, a catheter is placed in a vein for injecting the [18F]FECNT tracer. A total of five scans are taken, each one spanning from head to upper thigh. During the course of the scans, x-ray like pictures are obtained. The first scan takes about 100 minutes. Four additional 1-hour scans are done every 100 minutes. The total time for the scans is about 6 hours, and the total time for the entire procedure is about 9 hours. About 2 tablespoons of blood are drawn by needle stick at one time during the imaging. Subjects can leave the PET scanner between scans. They are asked to urinate every 2 hours for 6 hours from the time of tracer injection and to collect all the urine so that radioactivity can be measured.
Brain Imaging Study: Part 3
Part 3 of the study is the same as Part 1, except that two PET procedures are done on separate days, the second within 4 weeks of the first. In addition, participants may also under magnetic resonance imaging (MRI) scanning, a test that uses magnetic fields and radio waves to obtain pictures of the brain.
Panoramica dello studio
Descrizione dettagliata
Tipo di studio
Iscrizione
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
Maryland
-
Bethesda, Maryland, Stati Uniti, 20892
- National Institute of Mental Health (NIMH)
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Bambino
- Adulto
- Adulto più anziano
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
INCLUSION CRITERIA:
Healthy subjects ages 18-65
EXCLUSION CRITERIA-WHOLE BODY IMAGING:
Current diagnosis of psychiatric disease, substance dependence or severe systemic disease.
History of substance abuse within 6 months.
Abnormal laboratory tests.
Prior participation in other research protocols within the past year such that a radiation exposure together with the present study would exceed the annual limits.
Pregnancy and breast feeding.
HIV positive.
EXCLUSION CRITERIA-DYNAMIC BRAIN IMAGING:
Current diagnosis of psychiatric disease, substance dependence or severe systemic disease.
History of substance abuse within 6 months.
Abnormal laboratory tests.
Novocain allergy.
Prior participation in other research protocols within the past year such that a radiation exposure together with the present study would exceed the annual limits.
Any condition that increases increase risk for MRI (e.g., pacemaker, metallic foreign body in the eye).
Pregnancy and breast feeding.
HIV positive.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
Collaboratori e investigatori
Pubblicazioni e link utili
Pubblicazioni generali
- Abi-Dargham A, Gandelman M, Zoghbi SS, Laruelle M, Baldwin RM, Randall P, Zea-Ponce Y, Charney DS, Hoffer PB, Innis RB. Reproducibility of SPECT measurement of benzodiazepine receptors in human brain with iodine-123-iomazenil. J Nucl Med. 1995 Feb;36(2):167-75.
- Cloutier RJ, Smith SA, Watson EE, Snyder WS, Warner GG. Dose to the fetus from radionuclides in the bladder. Health Phys. 1973 Aug;25(2):147-61. doi: 10.1097/00004032-197308000-00009. No abstract available.
- Barrio JR, Huang SC, Melega WP, Yu DC, Hoffman JM, Schneider JS, Satyamurthy N, Mazziotta JC, Phelps ME. 6-[18F]fluoro-L-dopa probes dopamine turnover rates in central dopaminergic structures. J Neurosci Res. 1990 Dec;27(4):487-93. doi: 10.1002/jnr.490270408.
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
- 040204
- 04-M-0204
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su ANIMALE DOMESTICO
-
Turku University HospitalGE Healthcare; Blue Earth DiagnosticsCompletatoCarcinoma della prostataFinlandia
-
Norwegian University of Science and TechnologyUniversity Hospital of North Norway; Haukeland University Hospital; St. Olavs HospitalReclutamentoNeoplasie prostatiche | Metastasi neoplasticaNorvegia
-
Xuzhou Medical UniversitySconosciutoCancro alla prostata
-
University of Alabama at BirminghamCompletatoCancro alla prostata metastaticoStati Uniti
-
Marco PicardiFederico II UniversitySconosciutoLinfoma di Hodgkin classico | Linfoma diffuso a grandi cellule BItalia
-
HALO DiagnosticsCompletatoCancro alla prostataStati Uniti
-
Massachusetts General HospitalNational Cancer Institute (NCI)Completato
-
University of OklahomaMidwest Medical IsotopesTerminatoLinfoma non-HodgkinStati Uniti
-
University of VermontTerminatoNeoplasia prostaticaStati Uniti
-
Centre Henri BecquerelCompletatoCarcinoma polmonare non a piccole celluleFrancia